Efficacy and Safety of Rivaroxaban, Apixaban, and Edoxaban for Nonvalvular Atrial Fibrillation Based on Blood Coagulation Activity and Drug Plasma Concentration: SETtsu and North Osaka Multicenter Direct Oral AntiCoagulant (SET DOAC) Registry

• Ngā kaituhi matua: Michihiro Suwa (Author), Isao Morii (Author), Masaya Kino (Author), Yumie Matsui (Author), Masahiro Yoshinaga (Author), Hiroki Takahashi (Author), Masahiko Takagi (Author), Akira Yoshida (Author), Minoru Ichikawa (Author), Osamu Nakajima (Author), Mitsuhiro Tanimura (Author), Hisashi Shimoyama (Author), Hiroyuki Saitoh (Author), Isao Sasaki (Author), Takeshi Suzuki (Author), Satoshi Uemae (Author)
• Hōputu: Pukapuka
• I whakaputaina: MDPI AG, 2024-10-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

<b>Background:</b> The therapeutic effects of oral anticoagulant drugs for nonvalvular atrial fibrillation (NVAF) suggest that the three factor Xa (FXa) inhibitors may have distinct safety profiles, though this is not yet fully conclusive. This study investigated the current dosing of ri...